The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence.
- Author:
Hong-hao LI
1
;
Jie WANG
;
Zhao-hui DUAN
;
Hong-wei ZHANG
;
Ji-sheng CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Carcinoma, Hepatocellular; surgery; therapy; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Fluorouracil; administration & dosage; Follow-Up Studies; Hepatectomy; Hepatic Artery; Humans; Infusions, Intravenous; Interferon-alpha; therapeutic use; Iodized Oil; administration & dosage; Liver Neoplasms; surgery; therapy; Male; Middle Aged; Mitomycin; administration & dosage; Neoplasm Recurrence, Local; prevention & control; Portal Vein; Recombinant Proteins
- From: Chinese Journal of Oncology 2004;26(9):558-561
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence.
METHODSOn 75 HCC patients, PVC and HACE were respectively given at 2 weeks and 4 weeks after radical tumor resection. In 2nd week after surgery, 33 cases of them accepted Roferon-A treatment for 1 week. Seventy-two patients were followed up over 3 years. Effect of Roferon-A combined with HACE and PVC on postoperative recurrence rate was compared with that of HACE and PVC. Changes of T cell subsets in peripheral blood were examined with labeled monoclonal antibodies before and after hepatectomy or using interferon. Forty cholecystolithiasis patients received cholecystectomy were used as the controls.
RESULTSCD(3)(+) and CD(4)(+) cells in peripheral blood were reduced in patients with HCC. After hepatectomy, they declined further with decrease in CD(4)(+)/CD(8)(+) ratio. The results returned to pre-operative level at the end of 4th week after surgery. The CD(3)(+), CD(4)(+) cells and the CD(4)(+)/CD(8)(+) ratio increased remarkably following the use of Roferon-A. The 1-, 2- and 3-year recurrence rates of patients treated with HACE, PVC and Roferon-A in combination were 0%, 6.2% and 15.6%, respectively, while those treated with HACE and PVC were 5.0%, 12.5% and 27.5%, respectively.
CONCLUSIONPatients with HCC suffer from marked immuno-suppression which became ever more severe after hepatectomy, combined use of HACE, PVC and Roferon-A is superior to only HACE and PVC by decreasing the recurrence rate.
